Gilead Sciences

GILDNASDAQ

Antiviral chemistry, cell therapy, and partnered antibody-drug conjugates

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

GILD filings on EDGAR →

Cash & investments

$3.18B

at June 30, 2026 (10-Q)

Quarterly operating burn

No burn

operating cash flow positive, Jan–Jun 2026

Cash runway

—

not a runway: funded by operations

Shares outstanding

1.24B

cover page of the latest filing

Read from GILD's XBRL financial data; latest filing August 6, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

KITE-753 vs axi-cel: KITE-753 in Relapsed/refractory large B-cell lymphoma — primary completion

2031-05

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
BiktarvyHIVApprovedNot disclosed▼
Trodelvysolid tumors including breast cancerApprovedNot disclosed▼
Anitocabtagene autoleucelB-cell malignanciesPhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Gilead Sciences that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade GILD commission-free on Webullvia Webull · Affiliate

Comparable companies

AbbVieAmgenBristol Myers Squibb

Sponsored

Get premium GILD analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Gilead Sciences has 487 Phase 2 or 3 studies on ClinicalTrials.gov: 327 completed, 97 stopped early, 59 ongoing, 4 other.

327

Completed

97

Stopped early

59

Ongoing

Stopped early

  • NCT06682234Phase 2 · started 2025 · withdrawn

    obeldesivir in filovirus disease · n=0

    Reason given: The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.

  • NCT06784973Phase 2 · started 2025 · terminated

    Obeldesivir in rsv infection · n=4

    Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.

  • WONDERS2Phase 2/3 · started 2024 · terminated

    lepetegravir in hiv-1-infection · n=73

    Reason given: Sponsor decision to terminate study.

  • NCT06585150Phase 2 · started 2024 · terminated

    Obeldesivir in rsv infection · n=150

    Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.

  • NCT05996744Phase 2/3 · started 2023 · terminated

    Obeldesivir in covid-19 · n=3

    Reason given: Study was terminated by Sponsor; the decision was not due to any safety findings.

  • COSMICPhase 2 · started 2023 · terminated

    Edecesertib in cutaneous lupus erythematosus (cle) · n=20

    Reason given: Sponsor Decision

  • BIRCHPhase 3 · started 2022 · terminated

    Obeldesivir in covid-19 · n=468

    Reason given: The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.

  • ZUMA-25Phase 2 · started 2022 · terminated

    Brexucabtagene Autoleucel in relapsed/refractory waldenstrom macroglobulinemia · n=19

    Reason given: Sponsor decision to terminate study.

  • ELEVATE CRCPhase 2 · started 2022 · terminated

    Magrolimab in metastatic colorectal cancer · n=77

    Reason given: Sponsor decision to terminate study

  • ENHANCE-3Phase 3 · started 2022 · terminated

    Magrolimab in acute myeloid leukemia · n=378

    Reason given: Study was terminated due to futility

  • NCT05165771Phase 2 · started 2022 · withdrawn

    GS-5718 in rheumatoid arthritis · n=0

    Reason given: Sponsor decision to withdraw study.

  • ELEVATE TNBCPhase 2 · started 2021 · terminated

    Magrolimab in triple-negative breast cancer · n=92

    Reason given: Sponsor decision to terminate study.

  • NCT04892446Phase 2 · started 2021 · terminated

    Magrolimab in multiple myeloma · n=36

    Reason given: This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.

  • ELEVATELung&UCPhase 2 · started 2021 · terminated

    Magrolimab in solid tumor · n=106

    Reason given: Sponsor decision to terminate study

  • ELEVATE HNSCCPhase 2 · started 2021 · terminated

    Magrolimab in head and neck squamous cell carcinoma · n=193

    Reason given: Sponsor decision to terminate study

  • ENHANCE-2Phase 3 · started 2021 · terminated

    Magrolimab in acute myeloid leukemia · n=258

    Reason given: Study discontinued due to futility.

  • NCT04827589Phase 2 · started 2021 · withdrawn

    Tirabrutinib in chronic spontaneous urticaria · n=0

    Reason given: Development program terminated

  • NCT04778410Phase 2 · started 2021 · terminated

    Magrolimab in myeloid malignancies · n=54

    Reason given: Sponsor decision to terminate the study.

  • REDPINEPhase 3 · started 2021 · terminated

    Remdesivir in covid-19 · n=249

    Reason given: The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns.

  • SEALION1-IRPhase 3 · started 2020 · withdrawn

    Filgotinib in ankylosing spondylitis · n=0

    Reason given: Development program terminated

  • SEALION2-NAÏVEPhase 3 · started 2020 · withdrawn

    Filgotinib in ankylosing spondylitis · n=0

    Reason given: Development program terminated

  • NCT04501952Phase 3 · started 2020 · terminated

    RDV in covid-19 · n=584

    Reason given: The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.

  • ENHANCEPhase 3 · started 2020 · terminated

    Magrolimab in myelodysplastic syndromes · n=539

    Reason given: Study discontinued due to futility based on a planned analysis

  • FalconPhase 2 · started 2019 · terminated

    Tilpisertib in ulcerative colitis · n=19

    Reason given: Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage

  • PENGUIN 1Phase 3 · started 2019 · terminated

    Filgotinib in psoriatic arthritis · n=67

    Reason given: Development program terminated

  • PENGUIN 2Phase 3 · started 2019 · terminated

    Filgotinib in psoriatic arthritis · n=106

    Reason given: Development program terminated

  • NCT04024813Phase 2 · started 2019 · terminated

    Seladelpar in primary sclerosing cholangitis · n=1

    Reason given: Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).

  • PRIMISPhase 3 · started 2019 · terminated

    Cilofexor in primary sclerosing cholangitis · n=419

    Reason given: Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.

  • NCT03820258Phase 2 · started 2019 · terminated

    SOF/VEL/VOX in hepatitis c virus infection · n=21

    Reason given: SOF/VEL/VOX will not be evaluated in younger age groups.

  • NCT03551522Phase 2 · started 2018 · terminated

    Seladelpar in nash - nonalcoholic steatohepatitis · n=181

    Reason given: unexpected histological findings

  • NCT03472326Phase 2 · started 2018 · terminated

    GS-9131 in hiv-1-infection · n=21

    Reason given: GS-9131 did not meet the targeted antiviral response

  • NCT03434353Phase 2 · started 2018 · terminated

    Inarigivir Soproxil in chronic hepatitis b · n=123

    Reason given: Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.

  • ALPINE 2Phase 3 · started 2017 · terminated

    AZLI in pseudomonas aeruginosa respiratory tract infection/colonization · n=149

    Reason given: Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.

  • HUMBOLDTPhase 2 · started 2017 · terminated

    Filgotinib in noninfectious uveitis · n=74

    Reason given: Development program terminated

  • STELLAR-3Phase 3 · started 2017 · terminated

    SEL in nonalcoholic steatohepatitis · n=808

    Reason given: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.

  • STELLAR-4Phase 3 · started 2017 · terminated

    SEL in nonalcoholic steatohepatitis · n=883

    Reason given: This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.

  • NCT02983604Phase 1/2 · started 2017 · terminated

    GS-5829 in advanced estrogen receptor positive her2- breast cancer · n=14

    No reason recorded in the registry.

  • NCT02862574Phase 2 · started 2016 · terminated

    Andecaliximab in rheumatoid arthritis · n=15

    Reason given: Study was terminated by sponsor and decision was not due to any safety signals.

  • PBC-Phase 2Phase 2 · started 2016 · terminated

    Cilofexor in primary biliary cholangitis · n=71

    Reason given: The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).

  • NCT02953509Phase 1/2 · started 2016 · terminated

    Magrolimab in non hodgkin lymphoma · n=178

    Reason given: Study terminated early due to the magrolimab program discontinuation.

  • NCT02759562Phase 2 · started 2016 · terminated

    Andecaliximab in cystic fibrosis · n=6

    Reason given: Discontinuation of development for this indication

  • DISCOVERPhase 3 · started 2016 · terminated

    F/TAF in pre-exposure prophylaxis of hiv-1 infection · n=5399

    Reason given: Following review of accumulated safety data from DISCOVER and real-world use of F/TAF, the sponsor determined that the long-term safety of F/TAF had been demonstrated and no further safety monitoring within the study was required.

  • NCT02161679Phase 2 · started 2016 · withdrawn

    IMMU-132 infusion is administered to participants in one arm for the study in triple-negative breast cancer · n=0

    Reason given: FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated

  • NCT02701634Phase 2 · started 2016 · terminated

    ENTO in chronic graft versus host disease · n=66

    No reason recorded in the registry.

  • NCT02568683Phase 1/2 · started 2016 · terminated

    Entospletinib in non-hodgkin lymphoma · n=10

    No reason recorded in the registry.

  • NCT02536300Phase 3 · started 2016 · terminated

    Idelalisib in follicular lymphoma · n=96

    Reason given: Gilead has made the decision to close the study due to enrollment challenges

  • NCT02607228Phase 1/2 · started 2015 · terminated

    Alobresib in metastatic castrate-resistant prostate cancer · n=31

    No reason recorded in the registry.

  • NCT02600351Phase 3 · started 2015 · terminated

    LDV/SOF in hepatitis c virus infection · n=87

    Reason given: Due to lack of feasibility of enrolling participants, the study was terminated early.

  • NCT02609048Phase 2 · started 2015 · terminated

    Placebo Comparator in primary biliary cirrhosis (pbc) · n=41

    Reason given: Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.

  • NCT02258529Phase 2 · started 2015 · terminated

    Idelalisib in follicular lymphoma · n=10

    No reason recorded in the registry.

  • NCT02520284Phase 2/3 · started 2015 · terminated

    Andecaliximab in ulcerative colitis · n=165

    No reason recorded in the registry.

  • ENTO in AMLPhase 1/2 · started 2015 · terminated

    Entospletinib in acute myeloid leukemia · n=148

    No reason recorded in the registry.

  • NCT02404220Phase 1/2 · started 2015 · terminated

    Entospletinib in acute lymphoblastic leukemia · n=30

    No reason recorded in the registry.

  • NCT02377336Phase 2 · started 2015 · withdrawn

    GS-6615 in ischemic heart disease · n=0

    Reason given: Anticipated recruitment challenges

  • NCT02405442Phase 2 · started 2015 · terminated

    Andecaliximab in crohn's disease · n=187

    No reason recorded in the registry.

  • NCT01980875Phase 3 · started 2015 · terminated

    Idelalisib in chronic lymphocytic leukemia · n=57

    No reason recorded in the registry.

  • LIBERTY-HCMPhase 2/3 · started 2015 · terminated

    Eleclazine in hypertrophic cardiomyopathy · n=172

    No reason recorded in the registry.

  • NCT02300558Phase 3 · started 2014 · terminated

    Eleclazine in long qt syndrome type 3 · n=41

    No reason recorded in the registry.

  • NCT02044822Phase 2 · started 2014 · terminated

    Idelalisib in b-cell chronic lymphocytic leukemia (cll) with 17p deletion · n=102

    No reason recorded in the registry.

  • NCT01980888Phase 3 · started 2014 · terminated

    Idelalisib in chronic lymphocytic leukemia · n=311

    No reason recorded in the registry.

  • PANCRIT®-1Phase 3 · started 2013 · terminated

    IMMU-107 in metastatic pancreatic cancer · n=334

    Reason given: The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.

  • NCT01915472Phase 2 · started 2013 · withdrawn

    IMMU 130 in metastatic colorectal cancer · n=0

    Reason given: No participants enrolled

  • NCT01923311Phase 2/3 · started 2013 · terminated

    EVG in acquired immune deficiency syndrome (aids) · n=31

    No reason recorded in the registry.

  • NCT01796470Phase 2 · started 2013 · terminated

    Entospletinib in chronic lymphocytic leukemia · n=66

    Reason given: Study was terminated due to safety measures.

  • NCT01799889Phase 2 · started 2013 · terminated

    Entospletinib MM in chronic lymphocytic leukemia · n=326

    Reason given: Sponsor's decision to discontinue development of entospletinib.

  • NCT01605318Phase 1/2 · started 2013 · terminated

    Labetuzumab Govitecan (LG) in metastatic colorectal cancer · n=92

    No reason recorded in the registry.

  • RAINIERPhase 2 · started 2013 · terminated

    Simtuzumab in idiopathic pulmonary fibrosis · n=544

    Reason given: The Study was terminated due to lack of efficacy.

  • YosemitePhase 3 · started 2013 · terminated

    Placebo in indolent non-hodgkin's lymphomas · n=295

    No reason recorded in the registry.

  • BridalveilPhase 3 · started 2013 · terminated

    Idelalisib in indolent non-hodgkin's lymphomas · n=475

    No reason recorded in the registry.

  • NCT01672866Phase 2 · started 2012 · terminated

    Placebo in liver fibrosis due to nash · n=222

    No reason recorded in the registry.

  • NCT01659021Phase 3 · started 2012 · terminated

    Idelalisib in chronic lymphocytic leukemia · n=261

    No reason recorded in the registry.

  • NASHPhase 2 · started 2012 · terminated

    Placebo in liver fibrosis due to nash · n=259

    No reason recorded in the registry.

  • ATLASPhase 2 · started 2012 · terminated

    Simtuzumab in idiopathic pulmonary fibrosis · n=34

    Reason given: The Study was terminated due to lack of efficacy.

  • NCT01539291Phase 3 · started 2012 · terminated

    Idelalisib in chronic lymphocytic leukemia · n=161

    No reason recorded in the registry.

  • NCT01659047Phase 2 · started 2012 · withdrawn

    GS-1101 in chronic lymphocytic leukemia · n=0

    No reason recorded in the registry.

  • NCT01585688Phase 1/2 · started 2012 · terminated

    hLL1-DOX (IMMU-115) in non-hodgkin's lymphoma · n=13

    Reason given: Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued

  • NCT01479465Phase 2 · started 2011 · terminated

    Simtuzumab in colorectal cancer · n=266

    No reason recorded in the registry.

  • NCT01384383Phase 2 · started 2011 · terminated

    GS-5885 in chronic hepatitis c · n=248

    No reason recorded in the registry.

  • NCT01203930Phase 2 · started 2010 · terminated

    Idelalisib in chronic lymphocytic leukemia (cll) · n=105

    No reason recorded in the registry.

  • NCT01101594Phase 1/2 · started 2010 · terminated

    hLL1-DOX (the doxorubicin conjugate of milatuzumab) in multiple myeloma · n=17

    Reason given: Study was terminated due to lack of efficacy

  • NCT01101581Phase 1/2 · started 2010 · withdrawn

    Veltuzumab and 90Y-Epratuzumab Tetraxetan in non hodgkin's lymphoma · n=0

    Reason given: No subjects enrolled

  • NCT01090414Phase 1/2 · started 2010 · terminated

    Idelalisib in chronic lymphocytic leukemia · n=202

    No reason recorded in the registry.

  • NCT00650949Phase 1/2 · started 2009 · terminated

    CYT997 in glioblastoma multiforme · n=20

    Reason given: Strategic

  • ARTEMIS-PHPhase 3 · started 2009 · terminated

    Ambrisentan in idiopathic pulmonary fibrosis · n=40

    No reason recorded in the registry.

  • NCT00874796Phase 2 · started 2009 · terminated

    GS-9450 in hcv infection · n=307

    Reason given: Reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

  • NCT00907764Phase 2 · started 2009 · terminated

    regadenoson in heart disease · n=22

    Reason given: Slow enrollment

  • NCT00832507Phase 2 · started 2009 · terminated

    Cicletanine in pulmonary arterial hypertension · n=162

    No reason recorded in the registry.

  • ARTEMIS-IPFPhase 3 · started 2008 · terminated

    Ambrisentan in idiopathic pulmonary fibrosis · n=494

    Reason given: Lack of efficacy

  • NCT00814372Phase 2 · started 2008 · terminated

    MBX-102 in type 2 diabetes mellitus · n=242

    Reason given: MBX-102 did not meet the target efficacy profile of HbA1c change.

  • NCT00664378Phase 2 · started 2008 · terminated

    CYT997 in relapsed and refractory multiple myeloma · n=5

    Reason given: Difficulty enrolling patients

  • NCT00547066Phase 1/2 · started 2007 · terminated

    veltuzumab in purpura, thrombocytopenic, idiopathic · n=48

    No reason recorded in the registry.

  • NCT00499239Phase 1/2 · started 2007 · terminated

    GS-9219 in non-hodgkin's lymphoma · n=32

    Reason given: Unacceptable safety profile

  • DarusentanPhase 3 · started 2007 · terminated

    Darusentan in hypertension · n=661

    Reason given: Study DAR-312 did not meet its primary co-endpoints.

  • DarusentanPhase 3 · started 2006 · terminated

    Darusentan in hypertension · n=282

    Reason given: Study DAR-312 did not meet primary co-endpoints

  • NCT00113802Phase 2 · started 2004 · terminated

    Epratuzumab (hLL2- anti-CD22 humanized antibody) in waldenstrom macroglobulinemia · n=31

    Reason given: low accrual

  • NCT00077948Phase 3 · started 2003 · terminated

    Enoximone in heart failure, congestive · n=175

    No reason recorded in the registry.

  • NCT00051285Phase 3 · started 2002 · terminated

    Enoximone in heart failure, congestive · n=1800

    No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.